On September 17, 2026, NeurologyLive convened a clinical forum in Philadelphia titled "Recognizing and Treating Plexiform ...

Cerebral palsy (CP) is the most common motor disability of childhood, a group of permanent movement disorders caused by a ...

Benjamin Walter, MD, MBA, discusses how advances in biomarker testing and genetic characterization are informing Parkinson ...

Extracellular vesicle scores largely remained stable on placebo, whereas KP405 was associated with statistically significant but variable within-subject shifts in insulin signaling, neuroprotection, ...

New data from a Cure SMA survey showed that children treated with disease-modifying therapy soon after birth walk more often and have fewer comorbidities than those treated later. An updated ...

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Dravet syndrome treatment ...

Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions ...

Congressional passage would extend ACT for ALS programs and associated research grants through FY2031, sustaining federal ...

Full results from the phase 2b LUMA showed that investigational BIIB122/DNL151 did not slow confirmed clinical worsening in early-stage Parkinson's disease compared with placebo.

Cluster headache care remains hindered by migraine overlap, contributing to diagnostic delay and prolonged unmet need for ...

NeurologyLive Brain Games is a weekly quiz series that goes live every Sunday morning, featuring questions on a variety of ...

In MuSK+ gMG, MG-ADL and QMG improvements with inebilizumab persisted to week 52, including after crossover from placebo during the open-label period. Protocol-driven corticosteroid tapering to ≤5 ...